US investment-grade bond spreads — the premium highly rated companies pay to borrow relative to the government — were at 0.8 ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

(Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate ...

A total of US$241.7bn in Yankee bank debt has been issued in 2024, which is already one of the strongest years for the market in recent history, BMO said ... Biopharmaceutical company Gilead Sciences ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...

Reporting in recent days has indicated that the two top contenders to lead the Treasury Department in the second Trump administration are billionaires: hedge fund manager and Trump megadonor Scott ...

LB Denzel Perryman, OL Trey Pipkins III, former Chargers outside linebacker Larry English and many volunteers gathered at U.S ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...